🍄 Field Trip Health is the largest publicly traded, vertically integrated psychedelics company on the market.  Field Trip has a rapidly growing network of ketamine clinics and is developing novel psychedelic molecules and digital therapeutics.  In this deep dive episode, we interview Ronan Levy, the cofounder and executive chairman of field trip.  Ronan tells us:   How Field Trip stays competitive in the increasingly crowded clinic landscape    If Compass Pathway's aggressive patenting is a threat to Field Trip's business  If MindMed's vision of virtual trip-sitting is realistic    How investors should think about psychedelic companies that aggressively promote their stock  Why Field Trip may be undervalued relative to its peers   And much more    📺 Watch the video on YouTube:  https://youtu.be/8gtyZ8DWwNo📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/bromtalks   🐦 brom on twitter:  https://twitter.com/therealbrom 🎇 Clips and other stuff on Instagram:  https://instagram.com/bromtalks 💌 Email:   [email protected]    Disclaimer:  This video is not financial advice.  Brom holds shares in Field Trip Health, Mind Med, Cybin and Compass Pathways.